Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial

FDA approval is based on the positive results of TRITON3, a Phase 3, multicenter, open-label, randomized clinical trial of Rubraca® (rucaparib) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients This approval makes rucaparib an earlier treatment option...